Home > Press Releases > Obesity Drug Market

Obesity Drug Market Likely to Surpass USD 50.3 Billion by 2035

Report Code: HC-50417  |  Published in: Nov 2025, By MarketGenics  |  Number of pages: 366
Get PDF
Buy

A significant study discovering the market avenues on, “Obesity Drug Market Size, Share & Trends Analysis Report by Drug Type/Class (GLP-1 Receptor Agonists, GIP/GLP-1 Receptor Agonists (Dual Agonists), Lipase Inhibitors, Combination Therapies, Sympathomimetic Amines, Novel Mechanisms (Emerging)), Route of Administration, Prescription Type, Treatment Duration, Indication, Age Group, Mechanism of Action, End-Users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2026–2035” A holistic view of the market pathways in the obesity drug market underscores revenue acceleration through three key levers scalable product line extensions, high‑maturity strategic partnerships

Global Obesity Drug Market Forecast 2035:

According to the report, the global obesity drug market is projected to expand from USD 7.3 billion in 2025 to USD 50.3 billion by 2035, registering a CAGR of 21.3%, the highest during the forecast period. The Obesity Drug market is expanding rapidly all over the world, with the growing number of the chronic, rare, and complex diseases and the need to find targeted and individualized treatment. The rapid progress in biotechnology, genetic engineering and molecular biology has boosted the creation of biologics, gene therapies and cell-based treatment methods with superior efficacy, specificity and safety when compared with conventional small-molecule drug drugs.

Platform technologies such as mRNA, viral vectors, and AI-driven drug discovery systems have changed the process of drug development, which allows creating several therapeutic candidates based on a single investment, curtailing expenses and shortening timelines. Favorable regulatory policies, designation of breakthrough therapy, and expedited approval products further help in commercializing innovative therapies.

Besides, increasing R&D expenditure, strategic alliances and the development of new cure modalities are enhancing innovation, meeting unmet medical demands, and widening treatment choices amongst patients all around the globe. All these make the obesity drug market to be poised to experience growth and development all over the world.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Obesity Drug Market”

The growing health awareness and awareness of the risks related to obesity in different parts of the world is leading to the emergence of patients and health care providers who are demanding efficient alternatives to invasive surgery procedure such as bariatric surgery. Pharmacological treatment is safer and less disruptive as a method of weight control, especially when it is used in combination with lifestyle interventions. The increased access to FDA approved medications like GLP-1 receptor agonists, educational initiatives and online care provision are increasing the awareness and adoption of this therapy, thus leading to the expansion of the obesity drug market.

High cost and low affordability of treatment are still limiting the obesity drug market. Most obesity drugs, especially newer biologics, are sold at a premium cost, which is rarely fully covered by insurance, making it inaccessible to a significant number of patients. Out-of-pocket costs are capable of deterring patients regardless of whether they start or continue therapy, which is clinically recommended. Such a financial barrier is more acute in markets where there is low healthcare reimbursement or where the government is not funding it, limiting adoption even when there is clinical efficacy. These are limiting market expansion because they inhibit patient adoption and broader commercialization of obesity medications, particularly in lower-income groups.

The emergence of personalized medicine is an important solution in the management of obesity as it allows the treatment of an individual based on his genetics, metabolism, lifestyle, and comorbidities. By using genetic profiling, biomarkers, and digital health data, pharmaceutical firms can create more efficient and personalized treatments to obesity and enhance patient outcomes and minimize the trial-and-error prescribing of medications. As an example, The Mayo Clinic initiated a clinical trial (NCT06814938) called A Study of a Novel Precision Medicine Approach to Obesity, involving a saliva-based biomarker to predict response to Semaglutide 2.4 mg weekly in obese individuals.

Expansion of Global Obesity Drug Market

“Innovation, and public funding propel the global Obesity Drug market expansion”

  • The Obesity Drug market is growing rapidly worldwide because of the recent innovations in the pharmacological treatment, such as the discovery of GLP-1 receptor agonist, amylin analogs, and combinations that have been effective in increasing the weight loss outcome and metabolically improving the health of the body. As an example, In May 2025, Novo Nordisk and Septerna signed a deal to create oral small-molecule therapy to treat obesity and cardiometabolic diseases where Septerna can receive up to US$2.2 billion in payments and royalties and Novo Nordisk is in charge of development and commercialization through the Septerna GPCR discovery platform.
  • Government and insurance incentives may significantly stimulate the use of the Obesity Drug market by covering the out-of-pocket expenses of patients, promoting broader reimbursement coverage, and encouraging doctors to prescribe new therapeutic options, all of which will make obesity treatments more accessible and adopted by a broader population. Colorado enacted SB 25-048, Diabetes Prevention and Obesity Treatment Act, that requires large-group health insurance cover FDA-approved anti-obesity drugs, including at least one GLP-1 therapy, starting January 1, 2027. This law is expected to decrease the out-of-pocket payments of the patients, and therefore the treatments of obesity will become affordable and healthcare professionals will be motivated to prescribe these medicines.

Regional Analysis of Global Obesity Drug Market

  • North America has the biggest potential obesity drug market, because of a combination of the large prevalence of obesity in the region, good healthcare infrastructure and widespread availability of high-end treatment. Drug development and market adoption are further accelerated by the presence of major pharmaceutical firms, active clinical trials, and favourable regulatory processes. Moreover, raising patient awareness, covering anti-obesity medications in insurance programs, and the role of governmental efforts to fight obesity further contributes to the region superior growth potential of the obesity drug market.
  • The Asia Pacific region will record the largest rate of growth in the obesity drug market, due to the increase in the rate of obesity, urbanization and changing eating habits. The market adoption is being supported by the growing healthcare infrastructure, rising disposable income, and the rising access to new therapies. Also, increased knowledge on the health effects of obesity, state programs of weight loss, and international pharmaceutical corporations penetrating regional markets are increasing the pressure on pharmacological methods of weight loss in Asia-Pacific states.

Prominent players operating in the global obesity drug market are Altimmune Inc., Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim, Currax Pharmaceuticals LLC, Eli Lilly and Company, GlaxoSmithKline plc (GSK), Nalpropion Pharmaceuticals, Novo Nordisk A/S, Novo Nordisk A/S, Orexigen Therapeutics, Pfizer Inc., Rhythm Pharmaceuticals, Roche Holding AG, Sanofi S.A., Sciwind Biosciences, Structure Therapeutics, Takeda Pharmaceutical Company, Viking Therapeutics, Vivus Inc., Zealand Pharma A/S,  and Other Key Players.

The global Obesity Drug market has been segmented as follows:

Global Obesity Drug Market Analysis, By Drug Type/Class

  • GLP-1 Receptor Agonists
    • Semaglutide
    • Liraglutide
    • Dulaglutide
    • Exenatide
    • Others
  • GIP/GLP-1 Receptor Agonists (Dual Agonists)
  • Lipase Inhibitors
  • Combination Therapies
  • Sympathomimetic Amines
  • Novel Mechanisms (Emerging)

Global Obesity Drug Market Analysis, By Route of Administration

  • Injectable
  • Subcutaneous injection
  • Pre-filled pens
  • Auto-injectors
  • Oral
  • Tablets
  • Capsules
  • Extended-release formulations

Global Obesity Drug Market Analysis, By Prescription Type

Global Obesity Drug Market Analysis, By Treatment Duration

  • Short-term (< 3 months)
  • Medium-term (3-6 months)
  • Long-term (> 6 months)
  • Chronic/Maintenance therapy

Global Obesity Drug Market Analysis, By Indication

  • Obesity with Type 2 Diabetes
  • Obesity with Cardiovascular Disease
  • Obesity with Hypertension
  • Obesity with Sleep Apnea
  • Obesity with Dyslipidemia
  • Others

Global Obesity Drug Market Analysis, By Age Group

  • Pediatric
  • Adolescent
  • Adult
  • Geriatric

Global Obesity Drug Market Analysis, By Mechanism of Action

  • Appetite Suppressants
  • Metabolic Modulators
  • Fat Absorption Inhibitors
  • Incretin Mimetics
  • Combination Mechanisms

Global Obesity Drug Market Analysis, By End-users

  • Hospitals & Clinics
  • Specialty Weight Management Centers
  • Primary Care Practices
  • Endocrinology Clinics
  • Cardiology Centers
  • Home Healthcare
  • Research Institutions
  • Corporate Wellness Programs
  • Other End-users

Global Obesity Drug Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America
 

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Obesity Drug Market Outlook
      • 2.1.1. Obesity Drug Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Obesity Drug Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
        • 3.5.1.1. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising global obesity prevalence and greater health awareness
        • 4.1.1.2. Breakthrough pharmacotherapies (GLP-1s, oral small molecules) with strong efficacy
        • 4.1.1.3. Increased payer support, government incentives and demand for non-surgical options
      • 4.1.2. Restraints
        • 4.1.2.1. High drug costs and limited access/reimbursement
        • 4.1.2.2. Safety concerns and lack of long-term real-world data
    • 4.2. Key Trend Analysis
        • 4.2.1.1. Regulatory Framework
      • 4.2.2. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.2.3. Tariffs and Standards
      • 4.2.4. Impact Analysis of Regulations on the Market
    • 4.3. Value Chain Analysis
      • 4.3.1. Raw Material Suppliers
      • 4.3.2. Obesity Drug Manufacturers
      • 4.3.3. Distributors/ Commercializers
      • 4.3.4. End-users/ Customers
    • 4.4. Porter’s Five Forces Analysis
    • 4.5. PESTEL Analysis
    • 4.6. Global Obesity Drug Market Demand
      • 4.6.1. Historical Market Size - in Value (US$ Bn), 2020-2024
      • 4.6.2. Current and Future Market Size - in Value (US$ Bn), 2026–2035
        • 4.6.2.1. Y-o-Y Growth Trends
        • 4.6.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Obesity Drug Market Analysis, By Drug Type/Class
    • 6.1. Key Segment Analysis
    • 6.2. Obesity Drug Market Size (Value - US$ Bn), Analysis, and Forecasts, By Drug Type/Class, 2021-2035
      • 6.2.1. GLP-1 Receptor Agonists
        • 6.2.1.1. Semaglutide
        • 6.2.1.2. Liraglutide
        • 6.2.1.3. Dulaglutide
        • 6.2.1.4. Exenatide
        • 6.2.1.5. Others
      • 6.2.2. GIP/GLP-1 Receptor Agonists (Dual Agonists)
      • 6.2.3. Lipase Inhibitors
      • 6.2.4. Combination Therapies
      • 6.2.5. Sympathomimetic Amines
      • 6.2.6. Novel Mechanisms (Emerging)
  • 7. Global Obesity Drug Market Analysis, By Route of Administration
    • 7.1. Key Segment Analysis
    • 7.2. Obesity Drug Market Size (Value - US$ Bn), Analysis, and Forecasts, By Route of Administration, 2021-2035
      • 7.2.1. Injectable
      • 7.2.2. Subcutaneous injection
      • 7.2.3. Pre-filled pens
      • 7.2.4. Auto-injectors
      • 7.2.5. Oral
      • 7.2.6. Tablets
      • 7.2.7. Capsules
      • 7.2.8. Extended-release formulations
  • 8. Global Obesity Drug Market Analysis and Forecasts,By Prescription Type
    • 8.1. Key Findings
    • 8.2. Obesity Drug Market Size (Value - US$ Mn), Analysis, and Forecasts, By Prescription Type, 2021-2035
      • 8.2.1. Prescription-based
      • 8.2.2. Over-the-Counter (OTC)
      • 8.2.3. Specialty Prescription
  • 9. Global Obesity Drug Market Analysis and Forecasts, By Treatment Duration
    • 9.1. Key Findings
    • 9.2. Obesity Drug Market Size (Vo Value - US$ Mn), Analysis, and Forecasts, By Treatment Duration Method, 2021-2035
      • 9.2.1. Short-term (< 3 months)
      • 9.2.2. Medium-term (3-6 months)
      • 9.2.3. Long-term (> 6 months)
      • 9.2.4. Chronic/Maintenance therapy
  • 10. Global Obesity Drug Market Analysis and Forecasts, By Indication
    • 10.1. Key Findings
    • 10.2. Obesity Drug Market Size (Value - US$ Mn), Analysis, and Forecasts, By Indication, 2021-2035
      • 10.2.1. Obesity with Type 2 Diabetes
      • 10.2.2. Obesity with Cardiovascular Disease
      • 10.2.3. Obesity with Hypertension
      • 10.2.4. Obesity with Sleep Apnea
      • 10.2.5. Obesity with Dyslipidemia
      • 10.2.6. Others
  • 11. Global Obesity Drug Market Analysis and Forecasts, By Age Group
    • 11.1. Key Findings
    • 11.2. Obesity Drug Market Size (Value - US$ Mn), Analysis, and Forecasts, By Age Group, 2021-2035
      • 11.2.1. Pediatric
      • 11.2.2. Adolescent
      • 11.2.3. Adult
      • 11.2.4. Geriatric
  • 12. Global Obesity Drug Market Analysis and Forecasts, By Mechanism of Action
    • 12.1. Key Findings
    • 12.2. Obesity Drug Market Size (Value - US$ Mn), Analysis, and Forecasts, By Mechanism of Action, 2021-2035
      • 12.2.1. Appetite Suppressants
      • 12.2.2. Metabolic Modulators
      • 12.2.3. Fat Absorption Inhibitors
      • 12.2.4. Incretin Mimetics
      • 12.2.5. Combination Mechanisms
  • 13. Global Obesity Drug Market Analysis and Forecasts, By End-users
    • 13.1. Key Findings
    • 13.2. Obesity Drug Market Size (Value - US$ Mn), Analysis, and Forecasts, By End-users, 2021-2035
      • 13.2.1. Hospitals & Clinics
      • 13.2.2. Specialty Weight Management Centers
      • 13.2.3. Primary Care Practices
      • 13.2.4. Endocrinology Clinics
      • 13.2.5. Cardiology Centers
      • 13.2.6. Home Healthcare
      • 13.2.7. Research Institutions
      • 13.2.8. Corporate Wellness Programs
      • 13.2.9. Other End-users
  • 14. Global Obesity Drug Market Analysis and Forecasts, by Region
    • 14.1. Key Findings
    • 14.2. Obesity Drug Market Size (Value - US$ Mn), Analysis, and Forecasts, by Region, 2021-2035
      • 14.2.1. North America
      • 14.2.2. Europe
      • 14.2.3. Asia Pacific
      • 14.2.4. Middle East
      • 14.2.5. Africa
      • 14.2.6. South America
  • 15. North America Obesity Drug Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. North America Obesity Drug Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Drug Type/Class
      • 15.3.2. Route of Administration
      • 15.3.3. Prescription Type
      • 15.3.4. Treatment Duration
      • 15.3.5. Indication
      • 15.3.6. Age Group
      • 15.3.7. Mechanism of Action
      • 15.3.8. End-Users
      • 15.3.9. Country
        • 15.3.9.1. USA
        • 15.3.9.2. Canada
        • 15.3.9.3. Mexico
    • 15.4. USA Obesity Drug Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Drug Type/Class
      • 15.4.3. Route of Administration
      • 15.4.4. Prescription Type
      • 15.4.5. Treatment Duration
      • 15.4.6. Indication
      • 15.4.7. Age Group
      • 15.4.8. Mechanism of Action
      • 15.4.9. End-Users
    • 15.5. Canada Obesity Drug Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Drug Type/Class
      • 15.5.3. Route of Administration
      • 15.5.4. Prescription Type
      • 15.5.5. Treatment Duration
      • 15.5.6. Indication
      • 15.5.7. Age Group
      • 15.5.8. Mechanism of Action
      • 15.5.9. End-Users
    • 15.6. Mexico Obesity Drug Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Drug Type/Class
      • 15.6.3. Route of Administration
      • 15.6.4. Prescription Type
      • 15.6.5. Treatment Duration
      • 15.6.6. Indication
      • 15.6.7. Age Group
      • 15.6.8. Mechanism of Action
      • 15.6.9. End-Users
  • 16. Europe Obesity Drug Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Europe Obesity Drug Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Drug Type/Class
      • 16.3.2. Route of Administration
      • 16.3.3. Prescription Type
      • 16.3.4. Treatment Duration
      • 16.3.5. Indication
      • 16.3.6. Age Group
      • 16.3.7. Mechanism of Action
      • 16.3.8. End-Users
      • 16.3.9. Country
        • 16.3.9.1. Germany
        • 16.3.9.2. United Kingdom
        • 16.3.9.3. France
        • 16.3.9.4. Italy
        • 16.3.9.5. Spain
        • 16.3.9.6. Netherlands
        • 16.3.9.7. Nordic Countries
        • 16.3.9.8. Poland
        • 16.3.9.9. Russia & CIS
        • 16.3.9.10. Rest of Europe
    • 16.4. Germany Obesity Drug Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Drug Type/Class
      • 16.4.3. Route of Administration
      • 16.4.4. Prescription Type
      • 16.4.5. Treatment Duration
      • 16.4.6. Indication
      • 16.4.7. Age Group
      • 16.4.8. Mechanism of Action
      • 16.4.9. End-Users
    • 16.5. United Kingdom Obesity Drug Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Drug Type/Class
      • 16.5.3. Route of Administration
      • 16.5.4. Prescription Type
      • 16.5.5. Treatment Duration
      • 16.5.6. Indication
      • 16.5.7. Age Group
      • 16.5.8. Mechanism of Action
      • 16.5.9. End-Users
    • 16.6. France Obesity Drug Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Drug Type/Class
      • 16.6.3. Route of Administration
      • 16.6.4. Prescription Type
      • 16.6.5. Treatment Duration
      • 16.6.6. Indication
      • 16.6.7. Age Group
      • 16.6.8. Mechanism of Action
      • 16.6.9. End-Users
    • 16.7. Italy Obesity Drug Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Drug Type/Class
      • 16.7.3. Route of Administration
      • 16.7.4. Prescription Type
      • 16.7.5. Treatment Duration
      • 16.7.6. Indication
      • 16.7.7. Age Group
      • 16.7.8. Mechanism of Action
      • 16.7.9. End-Users
    • 16.8. Spain Obesity Drug Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Drug Type/Class
      • 16.8.3. Route of Administration
      • 16.8.4. Prescription Type
      • 16.8.5. Treatment Duration
      • 16.8.6. Indication
      • 16.8.7. Age Group
      • 16.8.8. Mechanism of Action
      • 16.8.9. End-Users
    • 16.9. Netherlands Obesity Drug Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Drug Type/Class
      • 16.9.3. Route of Administration
      • 16.9.4. Prescription Type
      • 16.9.5. Treatment Duration
      • 16.9.6. Indication
      • 16.9.7. Age Group
      • 16.9.8. Mechanism of Action
      • 16.9.9. End-Users
    • 16.10. Nordic Countries Obesity Drug Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Drug Type/Class
      • 16.10.3. Route of Administration
      • 16.10.4. Prescription Type
      • 16.10.5. Treatment Duration
      • 16.10.6. Indication
      • 16.10.7. Age Group
      • 16.10.8. Mechanism of Action
      • 16.10.9. End-Users
    • 16.11. Poland Obesity Drug Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Drug Type/Class
      • 16.11.3. Route of Administration
      • 16.11.4. Prescription Type
      • 16.11.5. Treatment Duration
      • 16.11.6. Indication
      • 16.11.7. Age Group
      • 16.11.8. Mechanism of Action
      • 16.11.9. End-Users
    • 16.12. Russia & CIS Obesity Drug Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Drug Type/Class
      • 16.12.3. Route of Administration
      • 16.12.4. Prescription Type
      • 16.12.5. Treatment Duration
      • 16.12.6. Indication
      • 16.12.7. Age Group
      • 16.12.8. Mechanism of Action
      • 16.12.9. End-Users
    • 16.13. Rest of Europe Obesity Drug Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Drug Type/Class
      • 16.13.3. Route of Administration
      • 16.13.4. Prescription Type
      • 16.13.5. Treatment Duration
      • 16.13.6. Indication
      • 16.13.7. Age Group
      • 16.13.8. Mechanism of Action
      • 16.13.9. End-Users
  • 17. Asia Pacific Obesity Drug Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Asia Pacific Obesity Drug Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Drug Type/Class
      • 17.3.2. Route of Administration
      • 17.3.3. Prescription Type
      • 17.3.4. Treatment Duration
      • 17.3.5. Indication
      • 17.3.6. Age Group
      • 17.3.7. Mechanism of Action
      • 17.3.8. End-Users
      • 17.3.9. Country
        • 17.3.9.1. China
        • 17.3.9.2. India
        • 17.3.9.3. Japan
        • 17.3.9.4. South Korea
        • 17.3.9.5. Australia and New Zealand
        • 17.3.9.6. Indonesia
        • 17.3.9.7. Malaysia
        • 17.3.9.8. Thailand
        • 17.3.9.9. Vietnam
        • 17.3.9.10. Rest of Asia Pacific
    • 17.4. China Obesity Drug Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Drug Type/Class
      • 17.4.3. Route of Administration
      • 17.4.4. Prescription Type
      • 17.4.5. Treatment Duration
      • 17.4.6. Indication
      • 17.4.7. Age Group
      • 17.4.8. Mechanism of Action
      • 17.4.9. End-Users
    • 17.5. India Obesity Drug Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Drug Type/Class
      • 17.5.3. Route of Administration
      • 17.5.4. Prescription Type
      • 17.5.5. Treatment Duration
      • 17.5.6. Indication
      • 17.5.7. Age Group
      • 17.5.8. Mechanism of Action
      • 17.5.9. End-Users
    • 17.6. Japan Obesity Drug Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Drug Type/Class
      • 17.6.3. Route of Administration
      • 17.6.4. Prescription Type
      • 17.6.5. Treatment Duration
      • 17.6.6. Indication
      • 17.6.7. Age Group
      • 17.6.8. Mechanism of Action
      • 17.6.9. End-Users
    • 17.7. South Korea Obesity Drug Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Drug Type/Class
      • 17.7.3. Route of Administration
      • 17.7.4. Prescription Type
      • 17.7.5. Treatment Duration
      • 17.7.6. Indication
      • 17.7.7. Age Group
      • 17.7.8. Mechanism of Action
      • 17.7.9. End-Users
    • 17.8. Australia and New Zealand Obesity Drug Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Drug Type/Class
      • 17.8.3. Route of Administration
      • 17.8.4. Prescription Type
      • 17.8.5. Treatment Duration
      • 17.8.6. Indication
      • 17.8.7. Age Group
      • 17.8.8. Mechanism of Action
      • 17.8.9. End-Users
    • 17.9. Indonesia Obesity Drug Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Drug Type/Class
      • 17.9.3. Route of Administration
      • 17.9.4. Prescription Type
      • 17.9.5. Treatment Duration
      • 17.9.6. Indication
      • 17.9.7. Age Group
      • 17.9.8. Mechanism of Action
      • 17.9.9. End-Users
    • 17.10. Malaysia Obesity Drug Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Drug Type/Class
      • 17.10.3. Route of Administration
      • 17.10.4. Prescription Type
      • 17.10.5. Treatment Duration
      • 17.10.6. Indication
      • 17.10.7. Age Group
      • 17.10.8. Mechanism of Action
      • 17.10.9. End-Users
    • 17.11. Thailand Obesity Drug Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Drug Type/Class
      • 17.11.3. Route of Administration
      • 17.11.4. Prescription Type
      • 17.11.5. Treatment Duration
      • 17.11.6. Indication
      • 17.11.7. Age Group
      • 17.11.8. Mechanism of Action
      • 17.11.9. End-Users
    • 17.12. Vietnam Obesity Drug Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Drug Type/Class
      • 17.12.3. Route of Administration
      • 17.12.4. Prescription Type
      • 17.12.5. Treatment Duration
      • 17.12.6. Indication
      • 17.12.7. Age Group
      • 17.12.8. Mechanism of Action
      • 17.12.9. End-Users
    • 17.13. Rest of Asia Pacific Obesity Drug Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Drug Type/Class
      • 17.13.3. Route of Administration
      • 17.13.4. Prescription Type
      • 17.13.5. Treatment Duration
      • 17.13.6. Indication
      • 17.13.7. Age Group
      • 17.13.8. Mechanism of Action
      • 17.13.9. End-Users
  • 18. Middle East Obesity Drug Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Middle East Obesity Drug Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Drug Type/Class
      • 18.3.2. Route of Administration
      • 18.3.3. Prescription Type
      • 18.3.4. Treatment Duration
      • 18.3.5. Indication
      • 18.3.6. Age Group
      • 18.3.7. Mechanism of Action
      • 18.3.8. End-Users
      • 18.3.9. Country
        • 18.3.9.1. Turkey
        • 18.3.9.2. UAE
        • 18.3.9.3. Saudi Arabia
        • 18.3.9.4. Israel
        • 18.3.9.5. Rest of Middle East
    • 18.4. Turkey Obesity Drug Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Drug Type/Class
      • 18.4.3. Route of Administration
      • 18.4.4. Prescription Type
      • 18.4.5. Treatment Duration
      • 18.4.6. Indication
      • 18.4.7. Age Group
      • 18.4.8. Mechanism of Action
      • 18.4.9. End-Users
    • 18.5. UAE Obesity Drug Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Drug Type/Class
      • 18.5.3. Route of Administration
      • 18.5.4. Prescription Type
      • 18.5.5. Treatment Duration
      • 18.5.6. Indication
      • 18.5.7. Age Group
      • 18.5.8. Mechanism of Action
      • 18.5.9. End-Users
    • 18.6. Saudi Arabia Obesity Drug Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Drug Type/Class
      • 18.6.3. Route of Administration
      • 18.6.4. Prescription Type
      • 18.6.5. Treatment Duration
      • 18.6.6. Indication
      • 18.6.7. Age Group
      • 18.6.8. Mechanism of Action
      • 18.6.9. End-Users
    • 18.7. Israel Obesity Drug Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Drug Type/Class
      • 18.7.3. Route of Administration
      • 18.7.4. Prescription Type
      • 18.7.5. Treatment Duration
      • 18.7.6. Indication
      • 18.7.7. Age Group
      • 18.7.8. Mechanism of Action
      • 18.7.9. End-Users
    • 18.8. Rest of Middle East Obesity Drug Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Drug Type/Class
      • 18.8.3. Route of Administration
      • 18.8.4. Prescription Type
      • 18.8.5. Treatment Duration
      • 18.8.6. Indication
      • 18.8.7. Age Group
      • 18.8.8. Mechanism of Action
      • 18.8.9. End-Users
  • 19. Africa Obesity Drug Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Africa Obesity Drug Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Drug Type/Class
      • 19.3.2. Route of Administration
      • 19.3.3. Prescription Type
      • 19.3.4. Treatment Duration
      • 19.3.5. Indication
      • 19.3.6. Age Group
      • 19.3.7. Mechanism of Action
      • 19.3.8. End-Users
      • 19.3.9. Country
        • 19.3.9.1. South Africa
        • 19.3.9.2. Egypt
        • 19.3.9.3. Nigeria
        • 19.3.9.4. Algeria
        • 19.3.9.5. Rest of Africa
    • 19.4. South Africa Obesity Drug Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Drug Type/Class
      • 19.4.3. Route of Administration
      • 19.4.4. Prescription Type
      • 19.4.5. Treatment Duration
      • 19.4.6. Indication
      • 19.4.7. Age Group
      • 19.4.8. Mechanism of Action
      • 19.4.9. End-Users
    • 19.5. Egypt Obesity Drug Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Drug Type/Class
      • 19.5.3. Route of Administration
      • 19.5.4. Prescription Type
      • 19.5.5. Treatment Duration
      • 19.5.6. Indication
      • 19.5.7. Age Group
      • 19.5.8. Mechanism of Action
      • 19.5.9. End-Users
    • 19.6. Nigeria Obesity Drug Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Drug Type/Class
      • 19.6.3. Route of Administration
      • 19.6.4. Prescription Type
      • 19.6.5. Treatment Duration
      • 19.6.6. Indication
      • 19.6.7. Age Group
      • 19.6.8. Mechanism of Action
      • 19.6.9. End-Users
    • 19.7. Algeria Obesity Drug Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Drug Type/Class
      • 19.7.3. Route of Administration
      • 19.7.4. Prescription Type
      • 19.7.5. Treatment Duration
      • 19.7.6. Indication
      • 19.7.7. Age Group
      • 19.7.8. Mechanism of Action
      • 19.7.9. End-Users
    • 19.8. Rest of Africa Obesity Drug Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Drug Type/Class
      • 19.8.3. Route of Administration
      • 19.8.4. Prescription Type
      • 19.8.5. Treatment Duration
      • 19.8.6. Indication
      • 19.8.7. Age Group
      • 19.8.8. Mechanism of Action
      • 19.8.9. End-Users
  • 20. South America Obesity Drug Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. South America Obesity Drug Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Drug Type/Class
      • 20.3.2. Route of Administration
      • 20.3.3. Prescription Type
      • 20.3.4. Treatment Duration
      • 20.3.5. Indication
      • 20.3.6. Age Group
      • 20.3.7. Mechanism of Action
      • 20.3.8. End-Users
      • 20.3.9. Country
        • 20.3.9.1. Brazil
        • 20.3.9.2. Argentina
        • 20.3.9.3. Rest of South America
    • 20.4. Brazil Obesity Drug Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Drug Type/Class
      • 20.4.3. Route of Administration
      • 20.4.4. Prescription Type
      • 20.4.5. Treatment Duration
      • 20.4.6. Indication
      • 20.4.7. Age Group
      • 20.4.8. Mechanism of Action
      • 20.4.9. End-Users
    • 20.5. Argentina Obesity Drug Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Drug Type/Class
      • 20.5.3. Route of Administration
      • 20.5.4. Prescription Type
      • 20.5.5. Treatment Duration
      • 20.5.6. Indication
      • 20.5.7. Age Group
      • 20.5.8. Mechanism of Action
      • 20.5.9. End-Users
    • 20.6. Rest of South America Obesity Drug Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Drug Type/Class
      • 20.6.3. Route of Administration
      • 20.6.4. Prescription Type
      • 20.6.5. Treatment Duration
      • 20.6.6. Indication
      • 20.6.7. Age Group
      • 20.6.8. Mechanism of Action
      • 20.6.9. End-Users
  • 21. Key Players/ Company Profile
    • 21.1. Altimmune Inc.
      • 21.1.1. Company Details/ Overview
      • 21.1.2. Company Financials
      • 21.1.3. Key Customers and Competitors
      • 21.1.4. Business/ Industry Portfolio
      • 21.1.5. Product Portfolio/ Specification Details
      • 21.1.6. Pricing Data
      • 21.1.7. Strategic Overview
      • 21.1.8. Recent Developments
    • 21.2. Amgen Inc.
    • 21.3. AstraZeneca PLC
    • 21.4. Boehringer Ingelheim
    • 21.5. Currax Pharmaceuticals LLC
    • 21.6. Eli Lilly and Company
    • 21.7. GlaxoSmithKline plc (GSK)
    • 21.8. Nalpropion Pharmaceuticals
    • 21.9. Novo Nordisk A/S
    • 21.10. Novo Nordisk A/S
    • 21.11. Orexigen Therapeutics
    • 21.12. Pfizer Inc.
    • 21.13. Rhythm Pharmaceuticals
    • 21.14. Roche Holding AG
    • 21.15. Sanofi S.A.
    • 21.16. Sciwind Biosciences
    • 21.17. Structure Therapeutics
    • 21.18. Takeda Pharmaceutical Company
    • 21.19. Viking Therapeutics
    • 21.20. Vivus Inc.
    • 21.21. Zealand Pharma A/S
    • 21.22. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation